Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder.
about
Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of ActionReview of intravesical therapies for bladder pain syndrome/interstitial cystitisEffect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium.Therapeutic use of botulinum toxin in migraine: mechanisms of action.Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder SyndromeA1 Adenosine Receptor-Mediated Inhibition of Parasympathetic Neuromuscular Transmission in Human and Murine Urinary BladderCommon theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladderNew developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.Characterization of bladder and external urethral activity in mice with or without spinal cord injury--a comparison study with rats.Purinergic signalling in the urinary tract in health and disease.Intravesical treatments of bladder pain syndrome/interstitial cystitis.Treatment of lower urinary tract symptoms: agents for intraprostatic injection.Targets for botulinum toxin in the lower urinary tract.Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of "overactive bladder".Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014.Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive Bladder.The potential role of unregulated autonomous bladder micromotions in urinary storage and voiding dysfunction; overactive bladder and detrusor underactivity.Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis.Changes in Management of Poorly Compliant Bladder in Botulinum Toxin A Era.Morphological changes in different populations of bladder afferent neurons detected by herpes simplex virus (HSV) vectors with cell-type-specific promoters in mice with spinal cord injury.Purinergic Signalling: Therapeutic Developments.Myofascial trigger points of the pelvic floor: associations with urological pain syndromes and treatment strategies including injection therapy.OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium.The role of capsaicin-sensitive C-fiber afferent pathways in the control of micturition in spinal-intact and spinal cord-injured mice.Characterization of mouse neuro-urological dynamics in a novel decerebrate arterially perfused mouse (DAPM) preparation.[Modern non-cosmetic treatment with botulinum toxins].Mucosal modulation of contractility in bladder strips from normal and overactive rat models and the effect of botulinum toxin A on overactive bladder strips.
P2860
Q26750535-C1CEC537-B898-4804-9F5A-0506753530E1Q26773549-C1A5FF2B-D786-45FD-A860-D50B3C21CEACQ33671401-487B8F3F-0A1F-403B-9B36-942F23515B63Q34419654-E6AC1AB6-173E-44D1-9EE9-44E4C849EF57Q35737565-89ED1E48-6A31-441A-ABB5-C9686E21ED7BQ36432305-19D15B03-0DFA-4EF7-A2DF-261C23067FF2Q36573132-D9EB1108-6ED0-47A2-891D-654DF72FE419Q36789948-CFBAB1D6-1474-4FAF-BCE5-549A5D14334BQ36902609-7F34DACD-F88D-427B-8DCB-2FC0BE9ADC37Q37620260-8F7B7487-BD86-481A-85D4-BD2C95BF4472Q38062822-261B4AA2-947C-4C47-B8D4-8BCAF055269FQ38071100-3568996A-CA90-4B05-BFCA-735F146AA9EDQ38115266-664094E1-6354-48ED-9ADF-DE35F906F1B9Q38231747-C1C3AFBF-6276-4C24-8C81-4ED369F7AC28Q38731392-10602B9F-3692-483F-8B11-54A57CA1272DQ38792373-B54ED17B-B984-467D-8550-257B6E734BC6Q38905184-4ABCFD19-2A68-4F69-8375-64A6F44399DDQ39210488-6E629867-A8D3-4755-9BD6-A734E520CB45Q39423373-2C1DA4BE-C706-4770-BF7C-01D02D325431Q41931257-2688123C-BE67-4A19-8201-1EE7989AEE23Q42367885-244B9EB2-EC49-4BE7-9B6E-4BEABD031822Q44755403-8C1CC8DD-B94A-4099-A93A-B40AF8F95B64Q45907261-88615240-7BAE-4719-98A1-C5F9352CFDB7Q47723052-61EDF10D-EABD-4126-9D66-EA46535897B8Q48245656-B1D58CC7-240E-4D94-8415-D535BCA65393Q48556994-3B481B24-AC8F-4C81-AF7D-07B10D9D9619Q51592596-C2A29AE5-3827-4343-B475-C4434272F1B6
P2860
Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Botulinum neurotoxin serotype ...... nerves in the urinary bladder.
@ast
Botulinum neurotoxin serotype ...... nerves in the urinary bladder.
@en
type
label
Botulinum neurotoxin serotype ...... nerves in the urinary bladder.
@ast
Botulinum neurotoxin serotype ...... nerves in the urinary bladder.
@en
prefLabel
Botulinum neurotoxin serotype ...... nerves in the urinary bladder.
@ast
Botulinum neurotoxin serotype ...... nerves in the urinary bladder.
@en
P2093
P2860
P1433
P1476
Botulinum neurotoxin serotype ...... nerves in the urinary bladder
@en
P2093
Ann T Hanna-Mitchell
Anthony J Kanai
Carly J McCarthy
Irina V Zabbarova
Lori A Birder
William C de Groat
P2860
P304
P356
10.1016/J.EURURO.2012.03.031
P407
P50
P577
2012-03-23T00:00:00Z